Books

The billion-dollar molecule

Hardcover - February 16, 1994

By Barry Werth

ISBN: 0671723278
Publisher: Simon & Schuster
Year: 1994
Pages: 448
Compare & Save from $64.32 total - 2 sellers competing

Select Condition

Condition Guide

Select a condition to see available offers

About This Book

An inside account of the start-up of a biotechnology company describes its struggle to bring a lifesaving drug to market, discussing the risky financing and profiling the venture capitalists involved. 30,000 first printing.
Marketplace from $64.32
Partner price may differ
Buy →

Product Details

Publisher Simon & Schuster
Publication date January 1, 1994
Language English
Print length 448 pages
ISBN-10 0671723278
ISBN-13 978-0671723279
Item Weight 1.6 pounds

All Marketplace Offers

2 sellers competing for your order

Filter:
Condition Seller Total (book + shipping) Delivery Action
Good

Shipping standard: ships in ≤2 business days · Returns: Ask seller before buying · Seller-error returns always accepted (30 days; seller covers return shipping).

AL
New seller · 0 reviews
$64.32
$59.33 book + $4.99 shipping
Arrives Nov 25-Nov 28 · Handling: 1 days
Estimated · shipping & returns
Select
Very Good

Shipping standard: ships in ≤2 business days · Returns: Ask seller before buying · Seller-error returns always accepted (30 days; seller covers return shipping).

MA
New seller · 0 reviews
$139.73
$136.74 book + $2.99 shipping
Arrives Nov 26-Nov 29 · Handling: 2 days
Estimated · shipping & returns
Select
No marketplace copies available in this condition.
Showing of 2 offers

Editorial Reviews

Editorial Review

From Library JournalWerth, a freelance writer on science and business issues, chronicles Joshua Boger's start-up of Vertex, a biotechnology company dedicated to the discovery of new drugs. Boger, a successful organic chemist with Merck, left his position as a senior director to establish Vertex. He recruited an exceptional group of researchers with the aim of integrating the most advanced disciplines in molecular biology to develop an immune-suppressing drug used in organ transplants and a potent HIV protease inhibitor to help thwart AIDS. Werth also discusses Vertex's financing and initial public stock offering. Recommended for science and business collections in public libraries and for special libraries in the pharmaceutical industry.- Bruce Slutsky, New Jersey Inst. of Tech. Lib., NewarkCopyright 1994 Reed Business Information, Inc.From BooklistIn a prose style emulating the speed and freneticism surrounding a marathon, Werth reveals the guts of the not-so-new field of biotechnology by focusing on a Cambridge, Massachusetts, company called Vertex. The company's story reads not like a thriller but like a clash of childish egos. It was started by a biochemist; recruiting top talent, Vertex then found its employees, products, and progress impeded by things both human and not. What began as a search for the ultimate immunosuppressant soon shifted into a drive for venture capital funds and partnerships; a major scientist then defected, and Vertex discovered its future promise lay in developing AIDS, anticancer, and anti-inflammation medicines rather than in immunosuppressants. The behind-the-scenes machinations make riveting reading. Barbara Jacobs From Kirkus Reviews A you-are-there account of the turbulent early days of Vertex, a high-tech, high-risk biotechnology firm. Werth (a freelance science and business writer) spent nearly four years following the travails of Vertex, where he seemingly had considerable access to its inner workings. His story begins in 1989, shortly after the company was launched with $10 million in venture capital--and with a plan to design superior new drugs, atom by atom if necessary. Vertex's chief, the brilliant and exuberant chemist Joshua Boger, is convinced that the company can design a safer immunosuppressive drug and capture the multimillion-dollar-a- year transplant market. Doing so will require brains, time, and lots of money, but Boger brings together the brains and raises the money that buys the time. Negotiating with pharmaceutical firms in England (Glaxo) and Japan (Chugai), he gives Vertex temporary financial security by striking a deal with Chugai and, in 1991, he takes Vertex public. Meanwhile, back at the lab, it turns out that the scientific side of the firm's endeavors aren't as straightforward as Boger's presentations to would-be investors might suggest: There are complications, rivalries, disappointments, and no end of technical problems, and, at the conclusion of the narrative, Vertex still has no
Shipping set per seller
Compare book + shipping totals for each offer
Seller-error returns
Returns accepted for seller errors. Ask the seller about change-of-mind returns
Partner purchases
MedicalBook.online handles payment, shipping and returns for its orders
Email Support
[email protected] for buyers and sellers